Quercetin nanoparticle complex attenuated diabetic nephropathy via regulating the expression level of ICACAM-1 on endothelium [Corrigendum]


The authors requested that the kidney images for Figure 2 on page 7804 be replaced due to a misunderstanding around the use of the images. The 17 kidney images were only intended as representative images to help emphasize the drug dispersity data shown in the corresponding bar graph was collected from kidneys. The bar graph represented the distribution of QUE/P via measurement of kidney homogenate radioactivity, but there was no intention to provide any morphological analysis of the kidneys and the authors apologize for any confusion this may have caused. The kidney images have been replaced with a representative image showing the kidney sample collection procedure used.

The corrected version of Figure 2 is shown below.

Figure 2 The distribution of quercetin/PEG-b-(PELG-g-PZLL) compound in rats.

Note: The distribution of quercetin/PEG-b-(PELG-g-PZLL) in rats and results expressed as mean ± standard deviation.

Abbreviations: PEG-b-(PELG-g-PZLL), poly(ethylene glycol)-b-(poly(ethylenediamine l-glutamate)-g-poly(ε-benzoxycarbonyl-l-lysine)); DPM, disintegrations per minute.